Breaking Down Toxicity Considerations for Non-Cytotoxic Payloads & Alternative Antibody Formats to Unlock Differentiated ADC Therapeutic Index - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Breaking Down Toxicity Considerations for Non-Cytotoxic Payloads & Alternative Antibody Formats to Unlock Differentiated ADC Therapeutic Index

9:30 am - Monday 12th October 2026

Understanding the need for ADC novelty to overcome patient resistance and deliver differentiated tolerability to widen therapeutic index
Evaluating the tolerability of ISACs and AOCs to assess the risk benefit profiles of alternate payload mechanisms
Understanding how considerations across bystander activity and target selection are crucial to manager toxicity of bispecific and peptide drug conjugates

Speakers:

Rakesh Dixit

Rakesh Dixit

President & Chief Executive Officer

Bionavigen Oncology